Synergistic effects of hypertonic saline and valproic acid in a lethal rat two-hit model

Journal of Trauma and Acute Care Surgery

Volumn 74, Issue 4, 2013, Pages 991-998

  Liu, Zhengcai ^a,e   Li, Yongqing ^a   Liu, Baoling ^a   Deperalta, Danielle K ^a   Zhao, Ting ^a   Chong, Wei ^a,d   Duan, Xiuzhen ^b   Zhou, Peter ^a   Velmahos, George C ^a   Alam, Hasan B ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d CHINA MEDICAL UNIVERSITY   (China)

^e FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hemorrhagic shock; hypertonic saline; rats; sepsis; valproic acid

Indexed keywords

INTERLEUKIN 1BETA; MYELOPEROXIDASE; PENTRAXIN 3; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUID RESUSCITATION; HEMORRHAGIC SHOCK; LONG TERM SURVIVAL; LUNG HOMOGENATE; MALE; MEAN ARTERIAL PRESSURE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONEAL CAVITY; PERITONEUM LAVAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; WESTERN BLOTTING;

ACUTE LUNG INJURY; ANIMALS; BLOTTING, WESTERN; C-REACTIVE PROTEIN; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; MALE; RATS; RATS, SPRAGUE-DAWLEY; RESUSCITATION; SALINE SOLUTION, HYPERTONIC; SERUM AMYLOID P-COMPONENT; VALPROIC ACID;

EID: 84876197334     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e31828583e3     Document Type: Article

References (40)

1. Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, Moldawer LL, Moore FA. Persistent inflammation and immunosuppres-sion: a common syndrome and new horizon for surgical intensive care. J Trauma. 2012;72:1491-1501.
2. Moore FA, Moore EE. Evolving concepts in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am. 1995;75:257-277.
3. Santry HP, Alam HB. Fluid resuscitation: past, present, and the future. Shock. 2010;33:229-241.
4. Alam HB, Rhee P. New developments in fluid resuscitation. Surg Clin North Am. 2007;87:55-72.
5. Committee on Fluid Resuscitation for Combat Casualties. Fluid Resuscitation: State of the Science for Treating Combat Casualties and Civilian Trauma. Report of the Institute of Medicine. Washington, DC: National Academy Press; 1999.
6. Ertmer C, Kampmeier T, Rehberg S, Lange M. Fluid resuscitation in multiple trauma patients. Curr Opin Anaesthesiol. 2011;24:202-208.
7. Bulger EM, Hoyt DB. Hypertonic resuscitation after severe injury: is it of benefit? Adv Surg. 2012;46:73-85.
8. Junger WG, Rhind SG, Rizoli SB, Cuschieri J, Shiu MY, Baker AJ, Li L, Shek PN, Hoyt DB, Bulger EM. Resuscitation of traumatic hemorrhagic shock patients with hypertonic salineVwithout dextranVinhibits neu-trophil and endothelial cell activation. Shock. 2012;38:341-350.
9. Bulger EM, May S, Kerby JD, Emerson S, Stiell IG, Schreiber MA, Brasel KJ, Tisherman SA, Coimbra R, Rizoli S, et al. Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial. Ann Surg. 2011;253:431-441.
10. The NHLBI Halts study of concentrated saline for patients with shock due to lack of survival benefit NIH News. 2009. Available at: http://www. nih.gov/news/health/mar2009/nhlbi-26.htm. Accessed August 25, 2012.
11. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138-150.
12. Manson J, Thiemermann C, Brohi K. Trauma alarmins as activators of damage-induced inflammation. Br J Surg. 2012;99(Suppl 1):12-20.
13. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104-107.
14. Russell JA. Management of sepsis. N Engl J Med. 2006;355:1699-1713.
15. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histone deacetylases as regulatorsof inflammation and immunity. Trends Immunol. 2011;32:335-343.
16. Li Y, Alam HB. Modulation of acetylation: creating a pro-survival and anti-inflammatory phenotype in lethal hemorrhagic and septic shock. J Biomed Biotechnol. 2011;2011:523481.
17. Lin T, Alam HB, Chen H, Britten-Webb J, Rhee P, Kirkpatrick J, Koustova E. Cardiac histones are substrates of histone deacetylase activity in hemorrhagic shock and resuscitation. Surgery. 2006;139:365-376.
18. Li Y, Liu B, Zhao H, Sailhamer EA, Fukudome EY, Zhang X, Kheirbek T, Finkelstein RA, Velmahos GC, deMoya M, et al. Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents. Shock. 2009;32:517-523.
19. Fukudome EY, Kochanek AR, Li Y, Smith EJ, Liu B, Kheirbek T, Lu J, Kim K, Hamwi K, Velmahos GCet al. Pharmacologic resuscitation promotes survival and attenuates hemorrhage-induced activation of extracellular signal-regulated kinase 1/2. J Surg Res. 2010;163:118-126.
20. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc. 2009; 4:31-36.
21. Kim K, Li Y, Jin G, Chong W, Liu B, Lu J, Lee K, Demoya M, Velmahos GC, Alam HB. Effect of valproic acid on acute lung injury in a rodent model of intestinal ischemia reperfusion. Resuscitation. 2012;83:243-248.
22. Li Y, Liu B, Gu X, Kochanek AR, Fukudome EY, Liu Z, Zhao T, Chong W, Zhao Y, Zhang D et al. Creating a "pro-survival" phenotype through epigenetic modulation. Surgery. 2012;152:455-464.
23. Kim K, Kim W, Rhee JE, Jo YH, Lee JH, Kim KS, Kwon WY, Suh GJ, Lee CC, Singer AJ. Induced hypothermia attenuates the acute lung injury in hemorrhagic shock. J Trauma. 2010;68:373-381.
24. He X, Han B, Liu M. Long pentraxin 3 in pulmonary infection and acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1039-L1049.
25. Mauri T, Coppadoro A, Bellani G, Bombino M, Patroniti N, Peri G, Mantovani A, Pesenti A. Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit Care Med. 2008;36:2302-2308.
26. He X, Han B, Bai X, Zhang Y, Cypel M, Mura M, Keshavjee S, Liu M. PTX3 as a potential biomarker of acute lung injury: supporting evidence from animal experimentation. Intensive Care Med. 2010;36:356-364.
27. Rittirsch D, Hoesel LM, Ward PA. The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol. 2007;81:137-143.
28. Remick DG, Newcomb DE, Bolgos GL, Call DR. Comparison of the mortality and inflammatory response of two models of sepsis: lipopoly-saccharide vs. cecal ligation and puncture. Shock. 2000;13:110-116.
29. Bickel WH, Wall MJ, Pepe PE, Martin RR, Ginger VF, Allen MK, Mattox KL. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med. 1994;331:1105-1109.
30. Kwan I, Bunn F, Roberts I;, WHO Pre-Hospital Trauma Care Steering Committee. Timing and volume of fluid administration for patients with bleeding following trauma. Cochrane Database Syst Rev. 2003: CD002245.
31. Alam HB, Stanton K, Koustova E, Burris D, Rich N, Rhee P. Effect of different resuscitation strategies on neutrophil activation in a swine model of hemorrhagic shock. Resuscitation. 2004;60:91-99.
32. Rhee P, Wang D, Ruff P, Austin B, DeBraux S, Wolcott K, Burris D, Ling G, Sun L. Human neutrophil activation and increased adhesion by various resuscitation fluids. Crit Care Med. 2000;28:74-78.
33. Savage SA, Fitzpatrick CM, Kashyap VS, Clouse WD, Kerby JD. Endo-thelial dysfunction after lactated Ringer's solution resuscitation for hem-orrhagic shock. J Trauma. 2005;59:284-290.
34. Diebel LN, Liberati DM, Ledgerwood AM, Lucas CE. Changes in lymph proteome induced by hemorrhagic shock: the appearance of damage-associated molecular patterns. J Trauma. 2012;73:41-51.
35. Wohlauer M, Moore EE, Silliman CC, Fragoso M, Gamboni F, Harr J, Accurso F, Wright F, Haenel J, Fullerton D, et al. Nebulized hypertonic saline attenuates acute lung injury following trauma and hemorrhagic shock via inhibition of matrix metalloproteinase-13. Crit Care Med. 2012; 40:2647-2653
36. Kochanek AR, Fukudome EY, Li Y, Smith EJ, Liu B, Velmahos GC, deMoya M, King D, Alam HB. Histone deacetylase inhibitor treatment attenuates MAP kinase pathway activation and pulmonary inflammation following hemorrhagic shock in a rodent model. J Surg Res. 2012; 176:185-194.
37. Zacharias N, Sailhamer EA, Li Y, Liu B, Butt MU, Shuja F, Velmahos GC, de Moya M, Alam HB. Histone deacetylase inhibitors prevent apoptosis following lethal hemorrhagic shock in rodent kidney cells. Resuscitation. 2011;82:105-109.
38. Butt MU, Sailhamer EA, Li Y, Liu B, Shuja F, Velmahos GC, DeMoya M, King DR, Alam HB. Pharmacologic resuscitation: cell protective mechanisms of histone deacetylase inhibition in lethal hemorrhagic shock. J Surg Res. 2009;156:290-296.
39. Neunaber C, Zeckey C, Andruszkow H, Frink M, Mommsen P, Krettek C, Hildebrand F. Immunomodulation in polytrauma and polymicrobial sepsisVwhere do we stand? Recent Pat Inflamm Allergy Drug Discov. 2011;5:17-25.
40. Sailhamer EA, Li Y, Smith EJ, Shuja F, Shults C, Liu B, Soupir C, deMoya M, Velmahos G, Alam HB. Acetylation: a novel method for modulation of the immune response following trauma/hemorrhage and inflammatory second hit in animals and humans. Surgery. 2008;144:204-216.